Total: $1,045.1M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
AEterna Laboratories Inc. (AELA; TSE:AEL) |
Private placement of common stock and warrants |
7.57S and 7.43W |
C$57 |
AEterna raised US$35.7M in two private placements, one with SGF Sante and Solidarity Fund QFL, and the other with Acqua Wellington Private Placement Fund Ltd.; the first one involved 7.3M shares and 7.3M warrants; the second one involved about 270,000 shares and about 133,000 warrants (4/9) |
Allos Therapeutics Inc. (ALTH) |
Private placement of common stock |
2.5S |
$15 |
Allos raised $15M in a private placement with Perseus-Soros Pharmaceutical Fund LP (4/24) |
Bioniche Pharma Group Ltd. (unit of Bioniche Life Sciences Inc.; Canada; TSE:BNC) |
Private placement of a convertible debenture |
N/A |
C$1.8 |
Bioniche Pharma received US$1.1M from ICC Venture Capital in the form of a 6% convertible debenture (4/24**) |
Biopure Corp. (BPUR) |
Private placement of common stock |
2.8S |
$20.7 |
Biopure raised about $20.7M with the placement of 2.8M shares with institutional investors (4/24) |
Genaera Corp. (GENR) |
Private placement of common stock |
6S |
$16.5 |
Genaera raised $16.5M in a private placement with institutional investors (4/9) |
Hyseq Pharmaceuticals Inc. (HYSQ) |
Private placement of common stock |
3.58S |
$15 |
Hyseq raised $15M in a private placement with undisclosed accredited investors (4/9) |
IDEC Pharmaceuticals Corp. (IDPH) |
Private placement of senior convertible notes |
Convertible into 8.2S |
$675 |
IDEC expects to gross $675M with the placement of notes that are convertible into 8.2M shares, or 9.1M shares if the overallotment option is exercised in full; the notes were offered to institutional buyers (4/24) |
Isis Pharmaceuticals Inc. (ISIP) |
Private placement of convertible subordinated notes |
ND |
$125 |
Isis raised $125M in the placement of notes, which are convertible into shares at $16.625 per share (4/26) |
Ligand Pharmaceuticals Inc. (LGND) |
Private placement of common stock |
4.25S |
$69.3 |
Ligand raised $69.3M in a private placement of 4.25M shares (4/17) |
Lynx Therapeutics Inc. (LYNX) |
Private placement of common stock |
14.6S and W for 5.8S |
$22.6 |
Lynx raised $22.6M in a private placement of 14.6M shares, as well as warrants for 5.8M shares (4/18) |
Nymox Pharmaceuticals Corp. (NYMX) |
Private placement of common stock |
N/A |
$0.819 |
Nymox raised $819,000 through a private placement with existing shareholders (4/3) |
Senesco Technologies Inc. (OTC BB: SENO) |
Private placement of common stock and warrants |
N/A |
$3.48 |
Senesco raised $3.48M through a private placement with certain accredited investors (4/24) |
Versicor Inc. (VERS) |
Private placement of common stock |
3S |
$44.9 |
Versicor raised $44.9M in a private placement (4/11) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. This chart does not include real estate or manufacturing plant financings. | ||||
@ Dates refer to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
N/A = Not available, applicable or reported. | ||||
OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||
